Gene Therapy: Bluebird’s Eli-Cel Efficacy Uncertain, Malignancy Risk Concerning, US FDA Says

 
• By Sue Sutter
Apples and oranges
Differences in the characteristics of clinical trial subjects and external controls complicate interpretation of eli-cel's efficacy, the FDA said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers